Menu
Recruiting NCT06263907

Stellate Ganglion Block for Prevention of Post Mastectomy Depression

No phase Interventional Mastectomy Pain, Acute Pain, Chronic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Stellate gangalion block.
Who it may be relevant to
Registry conditions: Mastectomy, Pain, Acute, Pain, Chronic. Basic parameters: 21 years — 65 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression

Overview

Complications after mastectomy include chronic pain and depression.

Detailed description

A mastectomy is surgery could be associated with complications include chronic pain and depression. In female breast cancer patients, the incidence of postoperative depression was 46.55%. Stellate ganglion block had been used for treating post-traumatic stress disorder (PTSD) and depression symptoms even in its prevention. Also, it used in treatment of chronic pain.

Interventions

  • Procedure Stellate gangalion block
    The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block

Primary outcome measures

  • incidence of postmastectomy depression [Time frame: 6 months postoperatively]
Secondary outcome measures (7)
  • incidence of postmastectomy depression [Time frame: 3 months postoperatively]
  • the need for postoperative antidepressant [Time frame: during the first 6 months postoperatively]
  • acute postoperative pain at the incision site (breast and the axilla) [Time frame: every 12 hour for the first 48 hour recorded]
  • chronic postmastectomy pain at the incision site [Time frame: at 3 and 6 months postoperatively]
  • incidence of nausea and vomiting [Time frame: during first 3 postoperative days]
  • Functional pain in the ipsilateral shoulder [Time frame: during the first 6 months postoperatively]
  • Any complications related to stellate ganglion injection [Time frame: within 1 day postoperatively]

Eligibility criteria

Inclusion criteria

  • Female patients
  • Age ranging from 18 to 65 years
  • American Society of Anesthesiologists (ASA) no more than II
  • Had unilateral cancer breast
  • Scheduled to do unilateral modified radical mastectomy

Exclusion criteria

  • Pregnant female
  • Existing Horner syndrome
  • Had any neuromuscular disease
  • Had allergy to local anesthetics
  • History of use of analgesics
  • Had any deformity or a previous surgery in the neck or ipsilateral arm or breast
  • Had any contraindication to the procedure (coagulation disorders, local infection, sepsis)
  • Had any contraindication to the sympathetic blockade (decompensate cardiopulmonary or hemodynamic disorders)
  • History of psychotic disorder including depression, bipolar disorder or personality disorder
  • Patient with Beck Depression Inventory (BDI) score more than 13

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Maha — Al Mansurah

Identifiers

NCT: NCT06263907 · stellate ganglion block

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗